{"id":12896,"date":"2019-04-23T16:46:02","date_gmt":"2019-04-23T14:46:02","guid":{"rendered":"https:\/\/www.hollandbio.nl\/?p=12896"},"modified":"2019-04-23T16:46:16","modified_gmt":"2019-04-23T14:46:16","slug":"cytura-therapeutics-to-target-genomic-instability-in-cancer","status":"publish","type":"post","link":"https:\/\/www.hollandbio.nl\/en\/nieuws\/cytura-therapeutics-to-target-genomic-instability-in-cancer\/","title":{"rendered":"Cytura Therapeutics to target genomic instability in cancer"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Cytura\nTherapeutics has successfully closed a Seed financing round. The funding is\nprovided by a syndicate led by Thuja Capital&nbsp;\nHealthcare (Seed) Fund II and includes BOM Brabant Ventures, the Centre\nfor Drug Design and Discovery (CD3) \u2013 KU Leuven and the Gemma Frisius Fund.\nCytura Therapeutics will use the new funding to advance its first proprietary\nsmall molecule program and to further expand their pipeline of new disruptive\ndrugs, targeting genomic instability.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The company\nwill be based at the Pivot Park Life Science Campus in Oss and collaborate with\nthe Amsterdam UMC and the Centre for Drug Design and Discovery (CD3) of the KU\nLeuven. Genomic instability is a major problem in cancer progression and\ntherapy resistance. By targeting genome instability this approach could be\napplied both as a stand-alone as in combinations therapy. On the latter, there\nis a large group of patients who will at first respond to the applied therapy\nand later on become resistant during treatment.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ad van\nGorp, co-founder of Cytura Therapeutics comments: &#8220;<em>One of the biggest issues in cancer treatment is that the disease has\nthe ability to change its nature over time caused by the increasing genomic\ninstability. Cytura&#8217;s R&amp;D efforts are focused on the development of small\nmolecules that will slow down or stop this genomic instability. I am committed\nto find this medicine which could lead to real advancements in the fight\nagainst cancer<\/em>.\u201d<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Management\nand shareholders<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Cytura Therapeutics is founded by Dr Ad van Gorp, former CEO of Dutch Lead Pharma, the Centre for Drug Design and Discovery (CD3) of the KU Leuven and Amsterdam UMC. In close collaboration with both organizations, Cytura Therapeutics aspires to advance it innovative first-in-class therapies targeting genomic instability of cancers.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Source: press release<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cytura Therapeutics has successfully closed a Seed financing round. The funding is provided by a syndicate led by Thuja Capital&nbsp; Healthcare (Seed) Fund II and includes BOM Brabant Ventures, the Centre for Drug Design and Discovery (CD3) \u2013 KU Leuven and the Gemma Frisius Fund. Cytura Therapeutics will use the new funding to advance its [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[43],"tags":[],"class_list":["post-12896","post","type-post","status-publish","format-standard","hentry","category-innovatieklimaat"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cytura Therapeutics to target genomic instability in cancer - hollandbio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/cytura-therapeutics-to-target-genomic-instability-in-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cytura Therapeutics to target genomic instability in cancer - hollandbio\" \/>\n<meta property=\"og:description\" content=\"Cytura Therapeutics has successfully closed a Seed financing round. The funding is provided by a syndicate led by Thuja Capital&nbsp; Healthcare (Seed) Fund II and includes BOM Brabant Ventures, the Centre for Drug Design and Discovery (CD3) \u2013 KU Leuven and the Gemma Frisius Fund. Cytura Therapeutics will use the new funding to advance its [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/cytura-therapeutics-to-target-genomic-instability-in-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"hollandbio\" \/>\n<meta property=\"article:published_time\" content=\"2019-04-23T14:46:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-04-23T14:46:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"hollandbio\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:site\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hollandbio\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/cytura-therapeutics-to-target-genomic-instability-in-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/cytura-therapeutics-to-target-genomic-instability-in-cancer\\\/\"},\"author\":{\"name\":\"hollandbio\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/833d6a25b39946e61c6101af1fa96fbb\"},\"headline\":\"Cytura Therapeutics to target genomic instability in cancer\",\"datePublished\":\"2019-04-23T14:46:02+00:00\",\"dateModified\":\"2019-04-23T14:46:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/cytura-therapeutics-to-target-genomic-instability-in-cancer\\\/\"},\"wordCount\":301,\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"articleSection\":[\"Innovatieklimaat\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/cytura-therapeutics-to-target-genomic-instability-in-cancer\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/cytura-therapeutics-to-target-genomic-instability-in-cancer\\\/\",\"name\":\"Cytura Therapeutics to target genomic instability in cancer - hollandbio\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\"},\"datePublished\":\"2019-04-23T14:46:02+00:00\",\"dateModified\":\"2019-04-23T14:46:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/cytura-therapeutics-to-target-genomic-instability-in-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/cytura-therapeutics-to-target-genomic-instability-in-cancer\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/cytura-therapeutics-to-target-genomic-instability-in-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cytura Therapeutics to target genomic instability in cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"name\":\"hollandbio\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\",\"name\":\"hollandbio\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"width\":218.664,\"height\":29.659,\"caption\":\"hollandbio\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/hollandbio\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/hollandbio\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/833d6a25b39946e61c6101af1fa96fbb\",\"name\":\"hollandbio\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cytura Therapeutics to target genomic instability in cancer - hollandbio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.hollandbio.nl\/en\/nieuws\/cytura-therapeutics-to-target-genomic-instability-in-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Cytura Therapeutics to target genomic instability in cancer - hollandbio","og_description":"Cytura Therapeutics has successfully closed a Seed financing round. The funding is provided by a syndicate led by Thuja Capital&nbsp; Healthcare (Seed) Fund II and includes BOM Brabant Ventures, the Centre for Drug Design and Discovery (CD3) \u2013 KU Leuven and the Gemma Frisius Fund. Cytura Therapeutics will use the new funding to advance its [&hellip;]","og_url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/cytura-therapeutics-to-target-genomic-instability-in-cancer\/","og_site_name":"hollandbio","article_published_time":"2019-04-23T14:46:02+00:00","article_modified_time":"2019-04-23T14:46:16+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png","type":"image\/png"}],"author":"hollandbio","twitter_card":"summary_large_image","twitter_creator":"@hollandbio","twitter_site":"@hollandbio","twitter_misc":{"Written by":"hollandbio","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/cytura-therapeutics-to-target-genomic-instability-in-cancer\/#article","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/cytura-therapeutics-to-target-genomic-instability-in-cancer\/"},"author":{"name":"hollandbio","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/833d6a25b39946e61c6101af1fa96fbb"},"headline":"Cytura Therapeutics to target genomic instability in cancer","datePublished":"2019-04-23T14:46:02+00:00","dateModified":"2019-04-23T14:46:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/cytura-therapeutics-to-target-genomic-instability-in-cancer\/"},"wordCount":301,"publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"articleSection":["Innovatieklimaat"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/cytura-therapeutics-to-target-genomic-instability-in-cancer\/","url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/cytura-therapeutics-to-target-genomic-instability-in-cancer\/","name":"Cytura Therapeutics to target genomic instability in cancer - hollandbio","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/#website"},"datePublished":"2019-04-23T14:46:02+00:00","dateModified":"2019-04-23T14:46:16+00:00","breadcrumb":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/cytura-therapeutics-to-target-genomic-instability-in-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.hollandbio.nl\/en\/nieuws\/cytura-therapeutics-to-target-genomic-instability-in-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/cytura-therapeutics-to-target-genomic-instability-in-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.hollandbio.nl\/en\/"},{"@type":"ListItem","position":2,"name":"Cytura Therapeutics to target genomic instability in cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.hollandbio.nl\/en\/#website","url":"https:\/\/www.hollandbio.nl\/en\/","name":"hollandbio","description":"","publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.hollandbio.nl\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.hollandbio.nl\/en\/#organization","name":"hollandbio","url":"https:\/\/www.hollandbio.nl\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","contentUrl":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","width":218.664,"height":29.659,"caption":"hollandbio"},"image":{"@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/hollandbio","https:\/\/www.linkedin.com\/company\/hollandbio\/"]},{"@type":"Person","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/833d6a25b39946e61c6101af1fa96fbb","name":"hollandbio"}]}},"_links":{"self":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/12896","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/comments?post=12896"}],"version-history":[{"count":0,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/12896\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/media?parent=12896"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/categories?post=12896"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/tags?post=12896"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}